of the malignant cells in the lymph nodes stained positively for p53. When the DNA ploidy pattern of the tumour was determined by flow cytometry, the aneuploid tumours in p53 positive and negative groups accounted for 69% and 45%, respectively (P<0.05). Proliferative activity of the tumour, as measured by labelling, was significantly higher (30.6± 12.0%) in the p53 positive group than that (25.1 ± 10.7%) in the p53 negative group (P<0.05). Thus, gastric cancer with a mutant p53 has high proliferative activity and metastasis to lymph nodes will probably occur.
Cancer occurs when there are multiple mutations in genes (Cairns, 1981; Bishop, 1987) . Some classes of genes normally function to prevent or suppress tumourigenesis and inactivation of such genes leads to an oncogenic state (Hollingsworth & Lee, 1991) . The p53 gene is one of these 'tumour suppressor genes', and p53 is a 53 kD nuclear protein which seems to regulate entry into the progression through the normal cell cycle (Mercer et al., 1984) . Studies of p53 expression in cultured cells suggested that increased levels are associated either with an abnormal mutated protein (Finlay et al., 1988) , or with stabilisation of the protein in a complex with viral antigens, e.g. SV40 large T antigen (Lane & Crawford, 1979) . Mutation of the p53 gene at a highly conserved sequence and alteration in the expression of p53 protein are frequent occurrences in human malignancies (Nigro et al., 1989; Bartek et al., 1990; Rodrigues et al., 1990; Iggo et al., 1990) .
There are basic data on p53 gene alterations in specimens of gastric cancer (Tamura et al., 1991; Kim et al., 1991; Yamada et al., 1991) . We examined the content of mutant p53 protein immunohistochemically using a large number of clinical samples, and associations with clinicopathological features were analysed. To clarify characteristics of the p53 positive tumour cells, we also analysed DNA ploidy patterns and cell proliferative activity determined by Ki-67 (Gerdes et al., 1983) Immunohistochemical staining ofp53 and Ki-67 PAb24O ) is a mouse monoclonal antibody that recognises an evolutionarily conserved epitope on p53, the epitope lies between amino acids 156 and 214 on murine p53. This antibody reacted with human, mouse, rat, hamster, bovine and chicken p53 in Western immunoblotting experiments . The avidin-biotin-peroxidase complex (ABC) method was used for staining. Sections were first washed in phosphate-buffered saline, pH 7.2 (PBS), and then incubated at room temperature with normal horse serum (Vector Laboratories, Burlingame, CA: 1:10 for 15 min). We then added PAb24O (Oncogene Science, New York: 1:50 overnight), biotinylated horse anti-mouse IgG (Vector Laboratories, Burlingame CA: 1:200 for 30 min), Avidinbiotin-peroxidase complex (Vector Laboratories: for 30 min). Peroxidase labelling was developed with a diaminobenzidine (DAB) and hydrogen peroxidase (H202), and the sections were counterstained with Mayer's hematoxylin. We used KUPL40 (Shirasawa et al., 1991) as the positive control, a carcinoma from a patient with familial polyposis coli transplanted into nude mice and known to contain a mutation in the p53 gene, detected by sequencing. Omission of the primary antibody served as the negative control.
To measure the proliferative activity, we used mouse monoclonal Ki-67 antibody (Dako, Copenhagen, Denmark: 1:100 overnight), then the procedures described above and the ABC method. We examined 1,000 nuclei in areas of the section with the highest labelling rates.
cytometer (Becton-Dickinson Immunocytometry Systems, Mountain View, CA). The fluorescent signals from 10,000 cells were collected and the results displayed in the form of a frequency distribution histogram (DNA histogram). A diploid pattern of the tumour cells was defined as a single GO/GI peak on the DNA histogram and an aneuploid pattern as at least one other clearly distinct GO/GI peak followed by a small G2 + M peak. The DNA index (DI) was defined as the ratio of the peak channel number of the GO/GI tumour population divided by the peak channel number of GO/GI diploid reference population. Data with a coefficient of variation (C.V.) over 8% and/or with excessive debris were excluded from study. The mean C.V. was 4.28 ± 1.82%.
Statistical analysis
Clinicopathological data was stored in an IBM 4381 mainframe computer. The Biomedical Computer Program (BMDP) was used for all statistical analyses (Dixon, 1988 positively for p53, the staining being similar in proportion to tumours showing invasion into deeper layers. However, a significant association was found between p53 overexpression and the metastatic spread to lymph nodes. p53-positive tumours were associated with a higher incidence of metastasis to lymph nodes (85%) than were p53-negative (64%, P <0.05). A p53-positive gastric cancer correlated with a higher rate of venous invasion (88%), compared with the p53-negative isolates (68%, P<0.05). As for metastasis to the liver, and peritoneal dissemination, there were no statistical differences.
We also investigated 26 metastatic lymph nodes using PAb240 (Table II) . The majority of the cancer cells in the metastatic lymph nodes stained positively for p53. In 17 of 18 cases with a p53-positive primary and in 7 of 8 with a p53 negative primary tumour, the metastatic nodes stained positively for p53 (Figure lb) .
As for the prognosis, the follow-up period was only 1-3 years, however, at this writing we found no significant differences between p53-positive and negative groups (data not shown). p53 and DNA ploidy or proliferative activity p53-positive isolates showed a significantly higher incidence of aneuploid pattern (69%) than did p53-negative isolates (45%, P<0.05, Table III ). The mean DNA index for the 
Discussion
In the present immunohistochemical study of human gastric cancer, we found that some diploid tumours or early stage gastric cancers showed an overexpression of p53, hence the possibility that mutation in this gene may occur, even in the early stage of cancer progression has to be considered. This notion is also supported by the finding that p53 mutations were involved in the formation of both carcinomas and adenomas which occur in familial polyposis coli (Shirasawa et al., 1991) .
Histologically, abnormal p53 protein expression was often recognised in cancer cells in tubular or medullar formation regardless of predominant histologic type. These findings are in close agreement with the report of Yasui et al. (1991) , in which loss of heterozygosity on chromosome Sq and 17p was frequent in cases of well differentiated types of gastric cancer.
The relationship between p53 overexpression and metastatic spread to lymph nodes was noted in breast cancer (Davidoff et al., 1991a) . In our study, there was a significant association between overexpression of p53 in gastric cancer and lymph node metastasis. Tumours with positive p53 staining frequently metastasised to lymph nodes and most metastatic lesions showed positive p53 staining. Furthermore, tumours with positive p53 staining had a higher proliferative activity than did those with which stained negatively. Cattoretti et al. (1988) reported a correlation between p53 immunoreaction and the Ki-67 score in cases of breast cancer. We also reported data that tumours with a high proliferative activity often metastasised to lymph nodes (Kakeji et al., 1991) . There are findings that nuclear phosphoprotein p53 is expressed in all cells late in the GI phase of the cycle and may regulate entry of the cells into the S phase (DNA synthesis) (Shohat et al., 1987) . Hence failure to appropriately regulate p53 expression may lead to an uncontrolled cell growth. In light of all these observations, the mutation of p53 seems to lead to activation of cell proliferation and the risk or lymph node metastasis is increased. The over-expressed mutant p53 is not merely a remnant of the mutational inactivation of p53 suppressor function, but also actively promotes growth of the tumour. As shown in Table  II , positive staining for p53 occurred only in the lymph nodes, in seven cases. As staining for p53 was positive in the early stage gastric cancers and there was some heterogeneity in this staining, the primary lesion may have contained a subpopulation of the mutant p53.
As for prognosis and p53 stainability, Scott et al. (1991) reported no difference in cases of colorectal carcinoma, however, Iwaya et al. (1991) did find differences in cases of breast carcinoma. Though we found no significant difference between p53 positive and negative tumours with regard to 2-year or 3-year survival rates, a longer follow-up is needed before conclusions can be reached.
Considering the association between genetic change and protein production, most of the cancers showing nuclear p53 immunoreaction also carried a mutation of the p53 gene, as noted in studies of breast, colorectal and lung cancer cell lines and tissues Rodrigues et al., 1990; Iggo et al., 1990; Davidoff et al., 1991b) . Though the number was small, Seruca et al. (1992) reported the association and some discrepancy between immunoreactivity and mutations in gastric cancer. Immunohistochemical analysis of malignant tissues appears to be a valid method which can be used to screen for the presence of mutant p53, however, it does have limitations. Data on the immunohistochemistry of p53 in gastric cancer may be clinically useful for getting some information on the metastatic potential to lymph nodes.
